Clinical Scorecard: Corneal Crosslinking Reimbursement In Its Tenth Year

At a Glance

Key Highlights

• FDA-approved epi-off corneal crosslinking is widely covered by payers but faces reimbursement challenges.
• New FDA-approved epi-on procedure (Epioxa) lacks payer coverage due to experimental status and high drug costs.
• Rising riboflavin drug costs and inconsistent reimbursement threaten financial sustainability of crosslinking programs.

Guideline-Based Recommendations

Diagnosis

• Identify progressive keratoconus or post-LASIK ectasia as indications for corneal crosslinking.

Management

• Perform FDA-approved epi-off crosslinking using riboflavin and UV-A light to halt disease progression.
• Consider epi-on crosslinking (Epioxa) when commercially available and covered by payers.

Monitoring & Follow-up

• Continuously monitor payer coverage policies and reimbursement rates for crosslinking procedures and drugs.
• Maintain staff training on documentation and billing to minimize denials and appeals.

Risks

• Financial risks include rising drug costs, inadequate reimbursement, and administrative hurdles with Category III CPT coding.
• Limited coverage for new epi-on procedures may delay patient access.

Patient & Prescribing Data

Patients with progressive keratoconus or post-refractive surgery ectasia requiring corneal strengthening

Epi-off procedure is FDA approved and covered by most payers; epi-on procedure currently lacks coverage and has substantially higher drug costs.

Clinical Best Practices

• Proactively monitor payer policies and reimbursement changes to maintain financial viability.
• Provide consistent internal staff training on billing and documentation requirements to reduce claim denials.
• Engage in contract negotiations and preauthorization processes to optimize reimbursement.
• Evaluate cost-benefit before adopting new technologies like epi-on crosslinking given current coverage limitations.

References

• FDA Approval of Corneal Crosslinking
• Epioxa FDA Approval 2025
• Payer Coverage Data
• Aetna Policy on Epi-on Crosslinking
• Anthem BCBS Policy on Epi-on Crosslinking
• Photrexa Drug Information